Outcome after resection for perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis: an international multicentre study

H. Jansson*, P.B. Olthof, A. Bergquist, M.A.P. Ligthart, S. Nadalin, R.I. Troisi, B.G. Koerkamp, R. Alikhanov, H. Lang, A. Guglielmi, M. Cescon, W.R. Jarnagin, L. Aldrighetti, T.M. van Gulik, E. Sparrelid, Perihilar Cholangiocarcinoma Collaboration Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)

Abstract

Background: Resection for perihilar cholangiocarcinoma (pCCA) in primary sclerosing cholangitis (PSC) has been reported to lead to worse outcomes than resection for non-PSC pCCA. The aim of this study was to compare prognostic factors and outcomes after resection in patients with PSC-associated pCCA and non-PSC pCCA. Methods: The international retrospective cohort comprised patients resected for pCCA from 21 centres (2000-2020). Patients operated with hepatobiliary resection, with pCCA verified by histology and with data on PSC status, were included. The primary outcome was overall survival. Secondary outcomes were disease-free survival and postoperative complications. Results: Of 1128 pCCA patients, 34 (3.0%) had underlying PSC. Median overall survival after resection was 33 months for PSC patients and 29 months for non-PSC patients (p = .630). Complications (ClavienDindo grade > 3) were more frequent in PSC pCCA (71% versus 44%, p = .003). The rate of posthepatectomy liver failure (21% versus 17%, p = .530) and 90-day mortality (12% versus 13%, p = 1.000) was similar for PSC and non-PSC patients. Conclusion: Median overall survival after resection for pCCA was similar in patients with underlying PSC and non-PSC patients. Complications were more frequent after resection for PSC-associated pCCA, with no difference in postoperative mortality.
Original languageEnglish
Pages (from-to)1751-1758
Number of pages8
JournalHPB
Volume23
Issue number11
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • HILAR CHOLANGIOCARCINOMA
  • RISK

Cite this